49results about How to "High promoter activity" patented technology

The present invention relates to pharmacologically active compounds which are capable of binding to nuclear hormone receptors and are useful for the stimulation of osteoblast proliferation and ultimately bone growth. This invention also relates to the use of such compounds for the treatment or prevention of diseases and / or disorders associated with nuclear hormone receptor families.

The invention discloses a promoter for a human tumor cell proliferation antigen Ki67 protein encoding gene. The invention concretely comprises the cloning, the sequence, the functions and an application of the promoter. The invention discloses a 1591bp sequence which contains the Ki67 gene promoter and is positioned at the positions from -820 to +771 on the 5' flank of the Ki67 gene. A deletion analysis method is used to respectively delete fragment by fragment from the 5' end and the 3' end of the 5' flank of the Ki67 gene to obtain DNA chopped fragments with different lengths. The fragments are inserted into the upper stream of a firefly luciferase reporter gene to construct a series of expression plasmids. The plasmids are transfected to four tumor cells and normal cells for transient expression, thereby determining that the Ki67 gene core promoter is positioned at the positions from -223 to +30 of the Ki67 gene. Due to high transcription activity and tumor specificity in the tumor cells, the Ki67 gene core promoter is a very useful tumor specificity promoter. The promoter can be used for adjusting and controlling therapeutic gene expression or for constructing conditional proliferative viruses, thereby realizing the selective killing of the tumor cells. The promoter is widely applied to the tumor targeted therapy.

Disclosed are a nucleic acid molecule of Corynebacterium glutamicum origin, having an improved promoter activity, which is operably linked to operon encoding aspartate kinase and aspartate semialdehyde dehydrogense, a vector containing the same, a transformant transformed with the vector, and a method for the production of L-lysine using the transformant.

The present application relates to a pharmaceutical composition, which comprises a ginseng-polygala tenuifolia willd drug pair or an extract thereof, and / or acorus tatarinowii-tuckahoe drug pair or an extract thereof. The present invention further relates to a preparation method of the pharmaceutical compositions, and uses of the pharmaceutical composition in preparation of drugs for memory enhancing or treatment of neurodegenerative diseases.

Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI / SNF) complexes in SS cells by increasing levels of wild type SS18 and / or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.

PCT No. PCT / DK97 / 00341 Sec. 371 Date Dec. 29, 1997 Sec. 102(e) Date Dec. 29, 1997 PCT Filed Aug. 22, 1997 PCT Pub. No. WO98 / 10079 PCT Pub. Date Mar. 12, 1998Expression vectors capable of being replicated in lactic acid bacterial cells comprising a promoter region comprising (a) a promoter sequence element the function of which is regulatable by an environmental or growth condition factor and (b) at least one further nucleotide sequence element, the position, orientation, presence and / or sequence of which element has a regulatory effect on the expression of a gene operably linked to the promoter region in which vectors the position, orientation, presence and / or sequence of at least one of said elements (a) or (b) is modified relative to the position, orientation, presence and / or sequence of the corresponding non-modified element whereby the expression of the gene is altered, and a lactic acid bacterium which is transformed with such a vector as defined above are provided. The recombinant cells containing such a regulatable or inducible gene expression system are useful as food or feed starter cultures or as strains for the production of gene products such as pharmaceutically or immunologically active compounds including oligo- or polypeptides derived from a Mycobacterium species including M. tuberculosis.

The human HLJ1 tumor suppressor gene is herein defined as regulated by promoter, enhancer, and silencer regions. HLJ1 promoter activity and gene expression are inversely correlated with metastatic ability. HLJ1 is highly expressed, and inducible, in cells with low metastatic ability and expressed to a lesser extent in highly metastatic cells. HLJ1 gene expression suppressed the growth of human lung adenocarcinoma cells in vitro, and inhibited tumor growth in vivo. It also impeded the motility of human adenocarcinoma cells and reduced the anchorage-independent growth capacity and invasiveness of metastatic lung adenocarcinoma cells. The degree to which human lung adenocarcinoma patients express HLJ1 predicts their survival prognosis and their probability of relapse.

The present disclosure relates to polynucleotides having promoter activity and applications thereof in the production of amino acids. Specifically, the present disclosure relates to a polynucleotide having promoter activity, a transcription expression cassette containing the polynucleotide, a recombinant expression vector, a recombinant host cell, a method for enhancing expression of a target gene, a method for preparing a protein, and a method for producing an amino acid. The polynucleotide with the promoter activity is a mutant of the polynucleotide with the sequence as shown in SEQ ID NO: 9, compared with the polynucleotide with the sequence as shown in SEQ ID NO: 9, the promoter activity of the mutant is remarkably enhanced, stable and efficient expression of a target gene can be promoted, and then downstream products can be stably and efficiently produced.

The invention discloses a mutant of a corynebacterium glutamicum glutamate dehydrogenase gene promoter and application of the mutant. The mutant has improved promoter activity compared with a wild type promoter. Therefore, the mutant can be used for enhancing the expression of a target gene, for example, the expression intensity of glutamate dehydrogenase can be enhanced by operably connecting the mutant with a glutamate dehydrogenase gene, so that the amino acid production efficiency of the recombinant strain is improved, and the application value is relatively higher.

Resistance genes and their encoded proteins from the wild potato, Solanum bulbocastanum, are disclosed. The genes and proteins are useful for conferring disease resistance to plants, particularly solanaceous species such as potato and tomato. In particular, the genes confer resistance to potato late blight. Compositions and methods that use the genes and proteins to enhance plant disease resistance are also disclosed, as are transgenic plants that comprise the resistance genes.

Disclosed are a nucleic acid molecule of Corynebacterium glutamicum origin, having an improved promoter activity, which is operably linked to operon encoding aspartate kinase and aspartate semialdehyde dehydrogense, a vector containing the same, a transformant transformed with the vector, and a method for the production of L-lysine using the transformant.

The present invention relates to a Purkinje cell-tropic viral vector in which a modified L7 promoter and a therapeutic gene are operably linked to a virus-based plasmid vector.

The invention discloses a method for raising expression of carbamoyl phosphate synthetase in HepGL liver cancer cells. The method comprises steps: CPS1 genome DNAs extracted from HepGL liver cancer cells are subjected to bisulfite treatment; the amplified CPS1 promoter area of the treated DNAs is subjected to methylation specific gene amplification; the amplified methylation sequences are subjected to sequencing; TALENs expression plasmids and non-methylation homologous plasmids which are homologous with the methylation loci are constructed according to base sequences around methylation loci, wherein, the homologous non-methylation sequence in the homologous plasmids is a mutation sequence wherein CG is mutated into CA; the TALENs expression plasmids and the homologous plasmids are subjected to transfection into HepGL liver cancer cells, HepGL liver cancer cells with transfection generation are screened, and subjected to Q-PCR and western blotting processing, and the expression amounts of mRNA of CPS1 and proteins in the cells are detected. The method can enhance the ammonia metabolism capability of HepGL liver cancer cells.

Disclosing a promoter of the protease MDTS9, which is induced by TGF-β, which is involved in the metabolism of extracellular matrix, and in which the expression of the gene thereof is elevated in renal failure model animals, which promoter is useful as a tool for screening an agent for treating and / or preventing chronic renal failure, as well as a method for screening an agent for treating and / or preventing chronic renal failure by selecting an inhibitor of the promoter.

Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI / SNF) complexes in SS cells by increasing levels of wild type SS18 and / or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.

The invention discloses a promoter of a 15kDa selenoprotein gene and a core area and application of the promoter. The promoter core area of the 15kDa selenoprotein gene disclosed by the invention is a 1238th to 1808th site of a sequence 1 in a sequence table; a promoter sequence can be a DNA (Deoxyribonucleic Acid) fragment as follows: the 1238th to 1808th site nucleotide sequence which at least comprises the sequence 1 in the sequence table, and in addition, from the 1238th site of the sequence 1, the sequence extends to a 5'-end of the sequence 1 according to the nucleotide sequence of the sequence 1, and then any DNA fragment of which the length is 571bp to 1808bp can be obtained. The promoter of the 15kDa selenoprotein gene and the core area of the promoter, which are provided by the invention, have great significances for preventing and / or treating endoplasmic reticulum stress related diseases.

A DNA comprising a 609 bp base sequence from −559 to +50 when the first base sequence of exon 1 of the midkine gene, a human retinoic acid-responsive growth / differentiation factor was set as +1, or a DNA comprising a 251 bp base sequence from −213 to +38 when the transcription initiation point of the c-erbB-2 gene belonging to the EGF receptor family and having a tyrosine kinase activity was set as +1 has a tumor-specific transcription activity, and the promoter activity thereof is high, and therefore is very important as a tumor-specific promoter for use in the suicide gene therapy that combines the use of a gene for a drug metabolizing enzyme and a prodrug for cancer therapy, the gene therapy of cancer using an expression vector that contains a gene encoding a cytokine, and the gene therapy of cancer using an oncolytic virus.

The invention relates to a muscle enhancer from a zebra fish muscle type creatine kinase b (ckmb) gene and application thereof. The enhancer can improve the activity of a promoter and can be used for preparing transgenic animals and applied to bioreactors.

The invention relates to a drug for lowering blood lipid. A structure of the drug is shown as a formula (1) to a formula (4) (please see the specification for the formula (1) to the formula (4)). Theinvention further relates to following application of a compound shown in the formula (1) to the formula (4) to: (1) preparation of drugs for treating atherosclerotic cardiovascular diseases; (2) preparation of drugs for adjusting blood glucose metabolism, wherein blood glucose metabolism adjusting refers to lowering of blood glucose, lowering of glycated serum protein, and lowering of glycated albumin; (3) preparation of drugs for reducing liver lipid accumulation and preventing fatty liver; and (4) preparation of preparations for inhibiting the expression of PCSK9 at the genetic level and improving the expression of LDLR.

It is intended to provide base sequences participating in the regulation of the expression of a promoter. It is also intended to modify a promoter based on the base sequence data to give a modified promoter having a high expression activity. Namely, a modified promoter constructed by inserting a first DNA fragment containing CCAATNNNNNN (SEQ ID NO:1) (a first base sequence) and a second DNA fragment containing CGGNNNNNNNNNGG (SEQ ID NO:2) (a second base sequence) into a promoter functioning in a filamentous fungus, wherein N in the base sequence denotes A (adenine), G (guanine), C(cytosine), or T (thymine).

Disclosed are a nucleic acid molecule of Corynebacterium glutamicum origin, having an improved promoter activity, which is operably linked to a gene encoding diaminopimelate dehydrogenase, a vector containing the same, a transformant transformed with the vector, and a method for the production of L-lysine using the transformant.

It is an object of the present invention to provide a novel protein and a DNA encoding the same. A compound or a salt thereof controlling an activity of the protein, and a neutralizing antibody controlling the activity of the protein are useful as, for example, a preventive and therapeutic drug for heart diseases.

The present invention provides novel myeloid cell specific promoters, and cis-acting elements that influence the activity of a myeloid cell specific promoters, as well as promoter-heterologous gene constructs and transfected myeloid cells which include the novel promoters and / or the novel cis-acting elements. The present invention also provides a method of transfecting myeloid cells and a method of producing a selected product within the transfected cells. The invention also includes a method for identifying factors that can regulate myeloid cell specific transcription.

The invention discloses a deletion mutant of maize phosphatidylinositol synthase gene promoter P-ZmPIS. The deletion mutant is named as a PZ7 promoter and is a continuous sequence comprising 467 nucleotides, close to an open reading frame, of the maize phosphatidylinositol synthase gene promoter P-ZmPIS, wherein the nucleotide sequence of the P-ZmPIS promoter is shown in SEQ ID No.1, and the nucleotide sequence of the PZ7 promoter is shown in SEQ ID No.2. The invention also discloses application of the promoter PZ7 in plant breeding for stress resistance, experiments show that PZ7 promoters promote the downstream genes to have NaCl and drought stress-induced characteristics in transformed cells, the deletion mutant has important application values in stress resistance genetic engineering breeding of salt-tolerant and drought-resistant plants.

A screening tool for an agent for promoting insulin production and / or an agent for increasing insulin content, wherein the tool is a G protein-coupled receptor exhibiting an activity of promoting insulin production by activation, or a cell expressing the polypeptide, is disclosed. Further, a method for screening an agent for promoting insulin production and / or an agent for increasing insulin content, comprising the steps of bringing the cell or a cell membrane thereof into contact with a substance to be tested, and analyzing whether or not the polypeptide is activated, is disclosed. The screening tool and the screening method are useful in screening a substance which increases insulin content and prevents and / or treats diabetes. Furthermore, a novel agent for increasing insulin content comprising as an active ingredient a substance obtained by the screening, is disclosed.